Global Clinical Trial Outsourcing Market 2024–2033

Reports Description

The Global Clinical Trial Outsourcing Market was valued at USD 43,102.4 million in 2024 and is expected to reach USD 91,210.1 million by 2033, at a CAGR of 7.46% during the forecast period 2024 - 2033.

To learn more about this report - request a sample report PDF

Clinical trial outsourcing is a model used to improve the efficiency of research. By outsourcing, the full clinical trial project management process is handled. The clinical research outsourcing model is evolving rapidly due to changing trends in the healthcare industry and the increasing number of contract research organisations across the globe.

Clinical Trial Outsourcing Market Growth Factors

Advantageous of Clinical Outsourcing

Many biotech and pharma research companies are increasingly adopting the clinical trial outsourcing model because it provides access to advanced trial capabilities to gain new functionality and expertise competencies. Clinical trial outsourcing provides below mentioned benefits, such as

Cost Saving: Conducting clinical trials in-house is very costly for pharmaceutical & biopharmaceutical and medical device companies and creates an extra financial burden on the end users. Therefore, end users opt for outsourcing because, in this process, end user companies no longer need to hire, train, or oversee clinical research staff as part of their in-house R&D teams or other infrastructure. All these activities and expenses come in the ambit of outsourcing contracts, and outsourcing companies are responsible. Furthermore, various other advantages, such as improvement in research levels and access to expert research staff, are expected to drive the adoption of clinical trial outsourcing during the forecast period. Clinical trial outsourcing is intended to improve the efficiency of research.

Access to Specialized Expertise: In outsourcing services, the end users get access to a team of specialized professionals with subject matter expertise and research professionals with decades of experience designing and conducting clinical trials. Clinical outsourcing organisations employ experts in various fields, including clinical research, data management, and regulatory compliance. Thus, the benefits mentioned above of clinical trial outsourcing are expected to drive the adoption globally, thereby driving market growth.

Increasing Drugs in Pipeline

The drug development industry is rapidly expanding across the globe due to growing innovations in the new drug developments. The growing prevalence of chronic diseases, increasing geriatric population, increasing incidences of cancers like diseases, rising prevalence of various pandemics and growing emphasis on healthcare by various governments across the globe are some of the factors expected to propel the demand for drug discovery and innovations in the drug development, thereby creating need for clinical trial outsourcing.

For instance, innovations in pharmaceutical drug development have increased exponentially in the last five years. In 2023, 9,500 new medicines underwent clinical trials and evaluation across the globe, and this number is expected to increase exponentially in the next ten years, thereby driving the demand for clinical trial outsourcing.

The drug development process is becoming more complex due to the growing complexity of gene therapies and antibody-drug conjugates, which in turn require more sophisticated clinical trials, thereby driving market growth.

Clinical Trial Outsourcing Market Restraints

Lack of Funding and Disadvantageous of Clinical Trial Outsourcing

The complete drug approval and trial process requires significant funding and investment. Many biopharma and medical institutions have a shortage of funding due to increasing research costs and complexity in the drug development process.

Furthermore, the drug development process and clinical trials are very lengthy and time-consuming, and there is little guarantee of success in clinical trials. These factors discourage new investment in the market, thereby hampering the overall market growth.

Furthermore, clinical trials require highly skilled professionals, and the remuneration of these professionals is very high due to growing inflation worldwide. Many developing and underdeveloped countries lack skilled clinical research specialists and research scientists, which in turn reduces the adaptation of clinical trials across these countries, thereby hampering the overall market growth.

There is a growing emergence of stringent regulations worldwide regarding clinical trial outsourcing due to increasing malpractices in the drug discovery process. Every country and region has its own set of rules and regulations.

In today’s globalized and interconnected market landscape, key players operating in the market are finding it very difficult to cope with such country-wide regulations, thereby reducing new investment in the market and hampering overall market growth.

Additionally, clinical trial outsourcing has certain disadvantages, such as the overdependence of third-party suppliers, the lack of coordination between end users and third-party clinical trial outsourcing companies, ethical issues related to clinical trials, and the growing side effects of clinical trials. These disadvantages are hampering the overall market growth.

Clinical Trial Outsourcing Market: Opportunities

Growing Investment in Pharmaceutical Research and Development and Collaboration between Pharmaceutical and Clinical Trial Organisations.

Increasing investment in pharmaceutical research and development due to the increasing demand for new drugs and the increasing prevalence of various chronic diseases across the globe. The complex drug development process and changing regulatory scenario are expected to drive the demand for clinical outsourcing during the forecast period.

For instance, by the end of 2023, the leading 20 pharmaceutical companies had spent more than USD 145 billion on pharmaceutical research and development, and this spending is expected to increase during the forecast period owing to growing investment in complex clinical study requirements, regulatory changes, and inflation.

Growing collaboration and strategic partnerships between clinical trial outsourcing companies and drug development companies are expected to propel the adaptation of clinical trial outsourcing. For instance, by July 2024, Pfizer had about 115 new drugs in the clinical trial process, many of which were outsourced to various clinical trial companies.

Pfizer has collaborated with many clinical trial outsourcing companies. For instance, Pfizer and ICON, an Ireland-headquartered clinical trial outsourcing company, have made a strategic partnership. Through this partnership, ICON provides clinical trial services to Pfizer and also provides global expertise in the planning, execution, management, and conduct of clinical trials.

Key players operating in the market heavily invest in advanced and emerging technologies for clinical trial outsourcing. Various emerging technologies such as Artificial Intelligence, Machine learning, predictive analytics, deep learning and the Internet of Things foster the accuracy and efficiency of clinical trials. Thus, the growing adoption of such emerging technologies is expected to create lucrative opportunities during the forecast period.

Clinical Trial Outsourcing Market: Segmentation Analysis

The Global Clinical Trial Outsourcing market is segmented by services, phase, study design, application, and end users. By Services, the Laboratory Services segment dominated the market and is expected to remain dominant during the forecast period. Laboratory services are the most crucial step in drug development and drug approvals.

It involves a variety of tests, such as stability studies, extractable and leachable analysis, detection of elemental impurities, method developmental analysis, biocompatibility, and packaging tests. The growing establishments of laboratories across the globe due to increasing investment in drug development are expected to create lucrative opportunities for market growth in this segment during the forecast period.

The site identification segment is expected to grow at the fastest CAGR during the forecast period. Site identification involves identifying and defining the site for drug development. Clinical trial organisations use various databases and advanced technologies to identify and select drug development sites. Analyzing past databases is essential for site selections.

By Phase, the global clinical trial outsourcing market is segmented into Phase I, II, III, and IV. Among these, the Phase III segment dominated the global clinical trial outsourcing market and is expected to keep its dominance during the forecast period. The Phase III trial is used to demonstrate the final approval of drugs.

Phase III is used to treat a large population. Phase III trials are conducted at many centres and drug development institutions with several hundred to several thousand patients for whom the drug is intended. Massive testing of a drug provides continued data on a drug's safety and efficacy.

Report Scope

Clinical Trial Outsourcing Market: Regional Insight

The global Clinical Trial Outsourcing market is segmented by region into North America, Asia Pacific, Europe, Middle East & Africa, and Latin America. Of these, the North American region held the highest market share in 2023 and is expected to keep its dominance during the forecast period owing to increasing investment in drug development centres and the growing number of clinical trial organisations in the region.

Various factors, such as the presence of a well-established pharmaceutical industry, increasing investment in new drug development, rise in the adaptation of advanced technologies for drug development, and presence of leading clinical trial organisations, are some of the factors boosting the market growth of this region.

Key countries such as the U.S., Canada, and Mexico are mainly boosting the market growth of this region. For instance, according to the data published by the National Library of Medicine, in 2023, more than 20,000 clinical trials were conducted in the U.S., and this number is expected to increase rapidly due to increasing global clinical trial activities in the U.S.

The U.S. dominated the North American clinical trial outsourcing market due to supportive government policies and growing emphasis by private and government organisations on new drug development.

Asia Pacific is expected to grow at the fastest CAGR during the forecast period. Key countries such as China, India, Japan, ASEAN, South Korea and Australia are mainly driving the market growth of this region.

Various factors, such as the rapidly expanding pharmaceutical industry, the growing number of drug discovery trials, increasing investment in new drug discovery, increasing awareness about healthcare, and an increasing population coupled with growing disposable incomes, are mainly boosting the demand for new drugs and discoveries, thereby creating market opportunities for clinical trial outsourcing in this region.

China dominated the Asia Pacific Clinical Trial Outsourcing market and is expected to maintain its dominance during the forecast period owing to supportive government policies regarding clinical trial outsourcing research.

Furthermore, the increasing geriatric population, the increasing prevalence of chronic diseases, and the well-established pharmaceutical industry, coupled with the availability of well-established healthcare and pharmaceutical industries in the country, are some of the factors mainly driving the market growth of this region.

India is expected to grow at the fastest CAGR during the forecast period owing to the growing number of clinical trials in the country. In 2023, there were 74,547 clinical trials registered and ongoing in India, and this number is expected to increase in upcoming years due to increasing investment in drug discoveries.

Furthermore, various supportive policies, such as Ayushman Bharat, provide universal healthcare coverage to all Indian citizens, thereby boosting the demand for new drugs. This, in turn, encourages clinical trial outsourcing, thereby boosting market growth.

List of the prominent players in the Clinical Trial Outsourcing Market:

• Albany Molecular Research
• EVOTEC
• Laboratory Corporation of America Holdings
• Genscript
• ICON plc
• IQVIA
• Thermo Fisher Scientific Inc.
• SGS Life Sciences
• Charles River Laboratories
• Parexel
• Syneos Health
• Medpace
• LabCorp
• KCR
• PRA Health Sciences
• WuXi AppTec
• Pharmaron
• Avance Clinical
• Pharmaron
• Others

The Clinical Trial Outsourcing Market is segmented as follows:

By Services

• Protocol Designing
• Site Identification
• Patient Recruitment
• Laboratory Services
• Bioanalytical Testing Services
• Clinical Trial Data Management Services
• Others

By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

By Study Design

• Interventional
• Observational
• Expanded Access

By Applications

• Cancer
• Cardiovascular Diseases
• Nervous System Diseases
• Infectious Diseases
• Musculoskeletal Disease
• Gastroenterology Diseases
• Others

By End-User

• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America